Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

References

• Adinarayana K, Ellaiah P. (2002). Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. J Pharm Pharm Sci 5:272–8
   PubMed Web of Science ®Google Scholar
• Agarwal S, Boddu SH, Jain R, et al. (2008). Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm 359:7–14
   PubMed Web of Science ®Google Scholar
• Aji Alex MR, Chacko AJ, Jose S, Souto EB. (2011). Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 42:11–18
   PubMed Web of Science ®Google Scholar
• Bharadwaj V, Kumar MNVR. (2006). Polymeric nanoparticles for oral delivery. New York, NY: Taylor and Francis
   Google Scholar
• Bolton SBC. (2004). Pharmaceutical statistics: practical and clinical applications. New York, NY: Marcel Dekker
   Google Scholar
• Cartiera MS, Johnson KM, Rajendran V, et al. (2009). The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30:2790–8
   PubMed Web of Science ®Google Scholar
• Chaudhary S, Garg T, Murthy RSR, et al. (2014). Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J Drug Target 22:871–82
   PubMed Web of Science ®Google Scholar
• Dong Y, Feng SS. (2005). Poly(d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:6068–76
   PubMed Web of Science ®Google Scholar
• Eason R. (2007). Pulsed laser deposition of thin films: applications-led growth of functional materials. New Jersey, NJ: Wiley publishers
   Google Scholar
• Fessi H, Puisieux F, Devissaguet JP, et al. (1989). Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1–4
   Web of Science ®Google Scholar
• Florence A. (1997). The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 14:259–66
   PubMed Web of Science ®Google Scholar
• Florence A, Jani PU. (1993). Particulate delivery: the challenge of the oral route. In: Rolland A, ed. Pharmaceutical particulate carriers: therapeutic applications. New York, NY: Marcel Dekker
   Google Scholar
• Garinot M, Fievez V, Pourcelle V, et al. (2007). PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 120:195–204
   PubMed Web of Science ®Google Scholar
• Govender T, Ojewole E, Naidoo P, Mackraj I. (2008). Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug Deliv 15:493–501
   PubMed Web of Science ®Google Scholar
• Ina Hubatsch E. (2007). Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2:2111–19
   PubMed Web of Science ®Google Scholar
• Jaidev LR, Krishnan UM, Sethuraman S. (2015). Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy. Mater Sci Eng C Mater Biol Appl 47:40–7
   PubMed Web of Science ®Google Scholar
• Joshi G, Kumar A, Sawant K. (2014). Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur J Pharm Sci 60:80–9
   PubMed Web of Science ®Google Scholar
• Katerinopoulos HE. (2004). The coumarin moiety as chromophore of fluorescent ion indicators in biological systems. Curr Pharm Des 10:3835–52
   PubMed Web of Science ®Google Scholar
• Kaur M, Malik B, Garg T, et al. (2015). Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv 22:328–34
   PubMed Web of Science ®Google Scholar
• Liu C, Shan W, Liu M, et al. (2015). A novel ligand conjugated nanoparticles for oral insulin delivery. Drug Deliv 23:1–11
   Web of Science ®Google Scholar
• Macal M, Sankaran S, Chun TW, et al. (2008). Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol 1:475–88
   PubMed Web of Science ®Google Scholar
• Mamo T, Moseman EA, Kolishetti N, et al. (2010). Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 5:269–85
   PubMed Web of Science ®Google Scholar
• Molla A, Mo H, Vasavanonda S, et al. (2002). In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother 46:2249–53
   PubMed Web of Science ®Google Scholar
• Montgomery DC. 2004. Introduction to factorial designs. New York, NY: John Wiley and Sons
   Google Scholar
• Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
   PubMed Web of Science ®Google Scholar
• Patel G, Shelat P, Lalwani A. (2016). Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment. Drug Delivery. [Epub ahead of print]. doi:10.3109/10717544.2016.1141260
   Google Scholar
• Prot M, Heripret L, Cardot-Leccia N, et al. (2006). Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother 50:3998–4004
   PubMed Web of Science ®Google Scholar
• Pukanud P, Peungvicha P, Sarisuta N. (2009). Development of mannosylated liposomes for bioadhesive oral drug delivery via M cells of Peyer’s patches. Drug Deliv 16:289–94
   PubMed Web of Science ®Google Scholar
• Rivolta I, Panariti A, Lettiero B, et al. (2011). Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles. J Physiol Pharmacol 62:45–53
   PubMed Web of Science ®Google Scholar
• Semete B, Booysen L, Lemmer Y, et al. (2010). In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 6:662–71
   PubMed Web of Science ®Google Scholar
• Senanayake TH, Warren G, Wei X, Vinogradov SV. (2013). Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates. J Control Rel 167:200–9
   PubMed Web of Science ®Google Scholar
• Shah U, Joshi G, Sawant K. (2014). Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. Mater Sci Eng C 35:153–63
   PubMed Web of Science ®Google Scholar
• Silva AC, Gonzalez-Mira E, Garcia ML, et al. (2011). Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces 86:158–65
   PubMed Web of Science ®Google Scholar
• Silva AC, Kumar A, Wild W, et al. (2012). Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Pharm 436:798–805
   PubMed Web of Science ®Google Scholar
• Soni G, Yadav KS. (2015). Applications of nanoparticles in treatment and diagnosis of leukemia. Mater Sci Eng C Mater Biol Appl 47:156–64
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shah L, Amiji MM. (2006). Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv 3:613–28
   PubMedGoogle Scholar
• Zhang L, Wang S, Zhang M, Sun J. (2013). Nanocarriers for oral drug delivery. J Drug Target 21:515–27
   PubMed Web of Science ®Google Scholar
• Zhou S, Feng X, Kestell P, et al. (2005). Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur J Pharm Sci 24:513–24
   PubMed Web of Science ®Google Scholar